quinta-feira, 1 de outubro de 2026
PesquisarExplore
Inteligência rastreável à fonte

Notícias em que pode confiar

Cada facto rastreado até à sua fonte, e verificado. Explore as empresas, os factos e as conclusões por trás das notícias.

O que estamos a observar

Conclusões que a nossa IA está a tirar dos factos rastreados — leia-as como interpretação, cada uma sustentada nos dados e nas entidades que menciona.

transformation· mixed

AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts

AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.

RentosertibEli LillyMER511Novo Nordisk
transformation· bullish

Enterprise Software Reorients Around AI Agents as Capital and Talent Concentrate

Enterprise software is being rebuilt around agentic AI. Venture money is flowing into vertical AI agent startups (Dextr AI, Latitude, Freehand, Groq) and into AI security and infrastructure. Meanwhile incumbents consolidate and reposition: Fortinet bought Virtue AI, Meta hired MongoDB's CEO to lead a new Enterprise Platform, and UiPath raised guidance. Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as ripe for disruption. They also warn that AI cannot be trusted with calculations, and that governance must be enforced by the system itself, particularly in regulated sectors.

Meta Enterprise PlatformDextr AIEnterprise AI Agentic MarketSprinklr, Inc.
transformation· mixed

Autumn 2026 Leadership Handovers and Insider Signalling in Corporate Governance

A cluster of executive and board transitions is reshaping leadership across consumer, financial and industrial companies. Berkshire Hathaway is passing the chairmanship from Warren Buffett to Howard Buffett. Heineken is installing Rafael Oliveira as CEO after KDP lost him, and ING and Brown-Forman are also reshuffling. Shareholder votes (EGMs, the AkzoNobel/Axalta merger vote, the Kneat take-private) and insider trades at Lineage, GameStop and Life360 sit alongside them. Boards present the changes as planned and orderly, and the insider trades are a mixed signal.

Howard BuffettKevin Patrick MarchettiJames GruberInsider Stock Purchases
transformation· mixed

Agentic AI Trust Gap: Identity, Copyright and Governance Pressures Meet an Executive-Led Spending Boom

Capital is flowing into AI-agent infrastructure, led by Baselayer's $35M Series A and Agentic Identity Suite. Baselayer's pitch is that agents must prove they act for legitimate people or businesses, as AI makes identity fraud cheaper and continuous. Meanwhile, copyright litigation (NYT v. OpenAI/Microsoft), AI-enabled state-linked hacking, agent spam (iLand), data-scavenging by xAI and low public trust in tech leave governance unsettled. Nvidia and Meta CEOs reject a coordinated slowdown, and hyperscaler spending continues.

Jonathan AwadBaselayerClément DelangueRory P. Read
cycle· mixed

AI Infrastructure Boom Lifts Power, Memory and Data-Center Names While Consumer and Speculative Tech Lag

Sell-side activity in mid-2026 centers on the AI infrastructure buildout. Digital Realty raised core FFO guidance, Evercore ISI set a Street-high $350 target on Bloom Energy, a bank reiterated a buy on NuScale (SMR), and Lynx published bullish notes on Micron and Sandisk, which coincided with a sympathy rally in ASML. Speculative frontier tech looks stretched: D-Wave trades at about 171x sales, and SpaceX shares are down more than 40% from their highs. Consumer names (Wendy's, GAP, Levi, Nike) show weak traffic and slow recovery. Large-cap biotech is being framed as an M&A-driven inflection point (Incyte-Vega, Goldman resuming Iovance at buy), a thread only loosely tied to the AI theme.

Digital Realty Trust, Inc.Bloom Energy Fuel CellsNuScale PowerMicron Technology Inc.
transformation· bullish

Oncology Earnings Momentum Meets AI-Driven Drug Discovery

Q2 2026 oncology results were strong. Novocure posted record revenue, Kiniksa raised its Arcalyst guidance, and the hematology and oncology guidance was narrowed and raised, though OPKO's softer Q3 outlook was one exception. Alongside this, AstraZeneca is describing a shift to agentic AI and automated 'lab of the future' systems for biologics design, and small-cap biotechs are financing through deals and cash runways (Treeline/Standard BioTools, ADC Therapeutics into 2028). Regulatory milestones such as the ivonescimab PDUFA date of 2026-11-14, together with advances in personalized mRNA vaccines, CAR-T and PARP1 inhibitors, support the pipeline outlook. Several listed events (rockets, dinosaurs, data center politics) are unrelated and add nothing to the story.

Personalized mRNA Skin Cancer VaccineEIK1004KLN-1010POHERDY (pertuzumab)
Sinais que acompanhamos
  • Satellite-Terrestrial Network Integration Acceleration

    Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

  • EPKINLY Regulatory-Clinical Success Cascade

    High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

  • Smart Home AI Platform Convergence

    Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products

  • AI Integration Acceleration

    Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances

Hipóteses em estudo
  • NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools

    88% confidence · por testar
  • Data center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers

    88% confidence · por testar
  • LLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations

    85% confidence · por testar
  • AI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance

    85% confidence · por testar
  • Hyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026

    85% confidence · por testar
Sources we've traced
all →
Source document

NextEra Energy Q4 Earnings Call Highlights

“NextEra Energy Q4 Earnings Call Highlights NextEra Energy logo Key Points Financials & guidance: NextEra reported 2025 adjusted EPS of $3.71 (up >8%) and is guiding 2026 adjusted EPS of $3.92–$4.02 (targeting the high end), while reaffirming an 8%+ CAGR in adjusted EPS through 2035 and dividend growth targets (~10% thr…”

Source document

‘Our funds are 20 years old’: limited partners confront VCs’ liquidity crisis

“‘Our funds are 20 years old’: limited partners confront VCs’ liquidity crisis Cash stashed for safe keeping in between mattresses. | Image Credits:jmbatt / Getty Images These days, it’s not easy to be a limited partner who invests in venture capital firms…”

Source document

Aeva Reports Fourth Quarter and Full Year 2025 Results

“Aeva Reports Fourth Quarter and Full Year 2025 Results Awarded Major Global Production Contract from Top 10 Passenger OEM Selected by Top 5 Passenger OEM for Global Vehicle Development Program Nvidia Selected Aeva as Reference LiDAR Sensor for DRIVE Hyperion Platform Doubled Revenue in 2025 Driven by Scaling Volume and…”

Source document

Eos Energy Enterprises Reports Fourth Quarter and Full Year 2025 Financial Results; Delivers More than 7x Year-Over-Year Revenue Growth and Initiates 2026 Revenue Guidance

“Eos Energy Enterprises Reports Fourth Quarter and Full Year 2025 Financial Results; Delivers More than 7x Year-Over-Year Revenue Growth and Initiates 2026 Revenue Guidance $58.0 million in record quarterly revenue with Q4 exceeding the first three 2025 quarters combined Secured over $240 million with nearly 1.1 GWh of…”

Source document

Stock market today: Dow, S&P 500, Nasdaq sink after hot PPI inflation print, indexes on track for monthly losses

“Stock market today: Dow, S&P 500, Nasdaq sink after hot PPI inflation print, indexes on track for monthly losses US stocks sank on Friday after a measure of wholesale inflation came in hotter than expected and Block's (XYZ) surprise shakeup turned the spotlight on AI disruption risks…”

Source document

Employers (EIG) Q4 2025 Earnings Call Transcript

“Employers (EIG) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Friday, Feb. 20, 2026 at 11 a.m…”

Onde as fontes discordam
all →
Shopify Inc.

Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.

Citigroup Inc.

Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.

Apple Inc.

The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.

Tesla Inc.

Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).

Tesla Inc.

Both facts report EPS (earnings per share) for Tesla Inc. for the identical fiscal period (Q1 2026) and observation date (2026-03-31), but state conflicting values: 0.13 USD/share vs. 0.41 USD. Same entity, same metric, same time period, different reported values.

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Every fact is traceable to the document it came from — see how we source every claim.

Latest News

View All →
Correção nas ações de chips de IA não freia acordos bilionários, consolidação e aposta estatal dos EUA
Analysis

Correção nas ações de chips de IA não freia acordos bilionários, consolidação e aposta estatal dos EUA

Wall Street corrigiu duramente os papéis de semicondutores de IA no fim de julho, mas os dados por trás do tombo mostram fornecimento garantido à Nvidia, dinheiro público entrando na GlobalFoundries e a fusão Skyworks-Qorvo já com liderança definida. Para o Brasil e Portugal, sem números locais no dossiê, o caso vale como estudo de caso de política industrial e de risco em ETFs alavancados.

LM Salvado•
Banco Central do Brasil mantém juros enquanto guerra no Irã adiciona riscos à inflação global
Política Monetária

Banco Central do Brasil mantém juros enquanto guerra no Irã adiciona riscos à inflação global

O Banco Central do Brasil interrompeu cortes de juros em março de 2026, citando novos riscos geopolíticos do conflito no Irã. O diretor de política monetária Nilton David alertou que a guerra pode exigir recalibração da estratégia de juros após a reunião de março, enquanto bancos centrais globais incluindo Fed e BCE também pausam reduções.

Nubank processa 100+ produtos em 2025 com IA, mas regulação FGTS freia crescimento de carteira para 10%
Fintech e Crédito Digital

Nubank processa 100+ produtos em 2025 com IA, mas regulação FGTS freia crescimento de carteira para 10%

O Nu Holdings lançou seu modelo de IA nuFormer em 2025, processando mais de 100 produtos e recursos. A ferramenta acelerou aquisição de clientes, mas mudanças na regulação do FGTS em novembro reduziram o crescimento esperado da carteira de 13-14% para 10%. Inter & Co captou 7 milhões de novos clientes em 2025, com coortes recentes transacionando mais rápido.

Investimentos de US$ 109 bilhões da Petrobras no pré-sal enfrentam risco de ativos encalhados
Energia e Transição

Investimentos de US$ 109 bilhões da Petrobras no pré-sal enfrentam risco de ativos encalhados

O plano de investimento 2026-2030 da Petrobras concentra US$ 109 bilhões em projetos de pré-sal de longa duração, mas enfrenta risco de ativos encalhados se a transição energética acelerar. Barris de águas profundas de alto custo podem se tornar antieconômicos contra fornecimento marginal em cenários de destruição acelerada de demanda por petróleo.

Ypê opera ERP sem suporte oficial da SAP e expõe cadeia de suprimentos a vulnerabilidades críticas
Enterprise Security

Ypê opera ERP sem suporte oficial da SAP e expõe cadeia de suprimentos a vulnerabilidades críticas

A Ypê, presente em 95% dos lares brasileiros, mantém sistemas SAP em suporte terceirizado via Rimini Street, sem acesso às correções de segurança oficiais do fornecedor. A estratégia deixa o ambiente ERP exposto a CVEs conhecidas que a SAP corrige, mas terceiros podem não replicar na mesma velocidade ou escopo. Especialistas classificam o risco como catastrófico em cenário de ataque direcionado.

Feito também para máquinas

Cada facto aqui é estruturado e rastreado à fonte — para que os sistemas de IA herdem a verdade de base, não afirmações reformuladas. Os mesmos factos que uma pessoa lê, um modelo pode consultar.

Obtenha via API →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,317 documentos-fonte arquivados
Consulte estes dados → isubstrate.com